[Jacqueline]

Pro-apoptotic targeted therapies in blood cancers

by Jacqueline on Mon Feb 23, 2015 5:01 pm

Just for information:

Medical research made progress. I read this (text in French),

Multiple myeloma and lymphoma are two mature B blood diseases whose current treatment is based on chemotherapy ... Three trials of therapies at Nantes University Hospital are using molecules specifically targeting the apoptotic machinery. These are oral molecules of type "BH-3 mimetic".

In addition to new therapeutic approaches based on the characterization of the tumor (determining Profile "apoptotic") this program could replace chemotherapy with an innovative and targeted therapy by identifying predictors of response.

More (in French):

http://www.dhu-oncogreffe.com/fr/actualites-immunologie/le-service-d-hematologie-laureat-des-palmes-de-la-medecine/

Full translation via Google Translate:

The winner of Hematology des Palmes Medicine 2015

The research on pro-apoptotic targeted therapies in mature B hematological led by Prof. Steven Le Gouill and Philippe Moreau (Clinical Hematology Service of Nantes University Hospital) and Dr. Martine Amiot of the research team of the Centre Cancer Research Angers Nantes are among the ten award winners for the 2015 Fins medicine.

The palms of medicine awarded annually the work of ten research teams to ten promising inventions that announce tomorrow's medicine. This distinction confirms the excellence of their expertise.

Multiple myeloma and lymphoma are two mature B hematological whose current treatment is based on chemotherapy. Research conducted by Dr. Martine Amiot team are based on the study of the deregulation of the mechanisms of cell death (apoptosis) the level of expression, regulation and interaction between the proteins of the Bcl-2 family, the intrinsic and extrinsic apoptotic pathways, and signal transduction pathways. This helps to identify therapeutic targets that are validated in the field of clinical research in the Division of Hematology (Prof. Philippe Moreau, CLIP2 label CNIB). Three trials directly from this work to date are open to inclusions at Nantes University Hospital. These three clinical trials using therapies using molecules specifically targeting the apoptotic machinery. These are oral molecules of type "BH-3 mimetic". In addition to new therapeutic approaches based on the characterization of the tumor (determining Profile "apoptotic") this program could replace chemotherapy with an innovative and targeted therapy by identifying predictors of response.

[Beacon Staff]

Re: Pro-apoptotic targeted therapies in blood cancers

by Beacon Staff on Tue Feb 24, 2015 7:40 am

Thank you for your posting, Jacqueline.

We believe the award relates to the research that was described, in part, in this paper:

C Touzeau et al, "The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma," Leukemia, 2014 (link to full text at PubMed)

ABT-199 is currently being developed as a potential new myeloma therapy by the U.S. pharmaceutical company AbbVie, the former pharmaceutical division of Abbott Laboratories.

There are currently three clinical trials of ABT-199 underway in multiple myeloma patients.